NeuroOne Medical Technologies files updated $6.75 million at-the-market offering

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC), with a market capitalization of $40.41 million, announced Friday that it has filed an updated prospectus supplement for the offer and sale of up to $6.75 million of its common stock through JonesTrading Institutional Services LLC. The shares may be sold from time to time under a Capital on Demand Sales Agreement, as part of an at-the-market (ATM) offering. According to InvestingPro data, the company maintains a healthy liquidity position with a current ratio of 2.13.

The company, based in Eden Prairie, Minnesota, originally entered into the sales agreement with JonesTrading on December 21, 2022. The ATM program allows NeuroOne to sell shares directly into the market as defined by Rule 415(a)(4) under the Securities Act of 1933. Despite operating at a loss in the last twelve months, InvestingPro analysis shows impressive revenue growth of 54.53% and moderate debt levels.

According to the filing, the shares will be offered pursuant to a registration statement, and sales will be made only through the updated prospectus. Honigman LLP, acting as counsel to NeuroOne, has provided a legal opinion regarding the shares included in the offering.

The company stated that this filing does not constitute an offer to sell or a solicitation of an offer to buy the securities in any jurisdiction where such actions would be unlawful prior to registration or qualification under applicable securities laws.

This information is based on a press release statement included in NeuroOne Medical Technologies Corporation’s filing with the Securities and Exchange Commission.

In other recent news, NeuroOne Medical Technologies Corp reported its third-quarter 2025 earnings, exceeding revenue expectations. The company achieved a revenue of $1.7 million, surpassing the anticipated $1.55 million, marking a 9.68% surprise. Additionally, NeuroOne’s earnings per share (EPS) improved to -$0.03, outperforming the forecasted -$0.05. These results highlight positive developments for the company, reflecting a stronger financial performance than analysts had projected. The earnings report demonstrates NeuroOne’s ability to exceed market expectations, which is crucial information for investors. Analyst firms have not provided further updates on upgrades or downgrades following these results. These recent developments indicate a noteworthy quarter for NeuroOne Medical Technologies Corp.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.